Newly emerging biomarkers for ovarian cancer (summarized in Table 3) include epithelial cell adhesion molecule (EPCAM), syndecans, R-spondin, and several G protein-coupled receptors (GPCRs), including the estrogen receptor GPER1, that are currently being investigated in pre-clinical studies. This evidence concerns the gene SDC1 and ovarian carcinoma.